An open label, multi-centre, post marketing surveillance (PMS) to monitor the safety and efficacy of INCRUSE administered in Korean subjects with chronic obstructive pulmonary disease (COPD) in usual practice (205163) First published 30/08/2016 Last updated 23/05/2024 EU PAS number:EUPAS14947 Study Finalised